Home › NDC Lookup › RxCUI directory › RxCUI 2622914

Bendamustine hydrochloride 25 MG/ML Injectable Solution [Vivimusta] — RxCUI 2622914

Name: Bendamustine hydrochloride 25 MG/ML Injectable Solution [Vivimusta] (RxCUI 2622914)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 2622914 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2622914

Official nameBendamustine hydrochloride 25 MG/ML Injectable Solution [Vivimusta]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asVivimusta 25 MG/ML Injectable Solution

FDA products mapped2

Package NDCs mapped2

Reported Medicaid activity (SDUD)117 prescriptions · 6 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Bendamustine Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Bendamustine is a chemotherapy drug used to treat two types of blood cancer in adults: chronic lymphocytic leukemia (CLL) and a slow-growing type called indolent B-cell non-Hodgkin...
No, bendamustine is always given as an IV infusion at a clinic, infusion center, or hospital — never at home. You'll receive it through a vein on two days in a row, followed by a r...
How will I receive this treatment — do I take it at home?
Nausea, fatigue, and fever are among the most common things people notice. Low blood counts are also very common — this includes low white blood cells, red blood cells, and platele...

📖 Read our full Bendamustine Injection guide →

🕸️ Concept Web — How Bendamustine hydrochloride 25 MG/ML Injectable S... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Bendamustine hydrochloride 25 MG/ML Injectable Solution [Vivimusta] RxCUI 2622914 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 2

The active substance itself — no strength, form, or brand attached yet.
- Bendamustine 134547 IN
- Bendamustine hydrochloride 1114693 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Vivimusta 2622910 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Bendamustine Injectable Solution 790322 SCDF
- Bendamustine hydrochloride Injectable Solution 2647666 SCDFP
- Bendamustine Injectable Product 1160009 SCDG
- Bendamustine hydrochloride Injectable Product 2662801 SCDGP
- Bendamustine Injectable Solution [Vivimusta] 2622913 SBDF
- Bendamustine hydrochloride Injectable Solution [Vivimusta] 2655938 SBDFP
- Vivimusta Injectable Product 2622912 SBDG
- Injectable Solution 316949 DF
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Bendamustine hydrochloride 25 MG/ML Injectable Solution 1726097 SCD
- Bendamustine hydrochloride 25 MG/ML 1726096 SCDC
- Bendamustine hydrochloride 25 MG/ML [Vivimusta] 2622911 SBDC

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Bendamustine hydrochloride 25 MG/ML Injectable Solution SCD · 1726097
Bendamustine hydrochloride 25 MG/ML SCDC · 1726096
Bendamustine Injectable Solution SCDF · 790322
Bendamustine hydrochloride Injectable Solution SCDFP · 2647666
Bendamustine Injectable Product SCDG · 1160009
Bendamustine hydrochloride Injectable Product SCDGP · 2662801

Brand-Name Concepts

Bendamustine hydrochloride 25 MG/ML [Vivimusta] SBDC · 2622911
Bendamustine Injectable Solution [Vivimusta] SBDF · 2622913
Bendamustine hydrochloride Injectable Solution [Vivimusta] SBDFP · 2655938
Vivimusta Injectable Product SBDG · 2622912
Vivimusta BN · 2622910

📦 FDA Products & Package NDCs

2 products · 2 package NDCs

2 package NDCs map to RxCUI 2622914 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
24338-0270-01	1 VIAL, MULTI-DOSE in 1 CARTON (24338-270-01) / 4 mL in 1 V...	VIVIMUSTA	Azurity Pharmaceuticals, Inc.	2025-04-01
71225-0120-01	1 VIAL, MULTI-DOSE in 1 CARTON (71225-120-01) / 4 mL in 1 V...	VIVIMUSTA	Slayback Pharma LLC	2022-12-07

Observed labelers: Azurity Pharmaceuticals, Inc. (1) · Slayback Pharma LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J9056	Inj, vivimusta, 1 mg	2	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.